The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

When you get a diagnosis of multiple myeloma, you may not even know what it is. Find out why this type of cancer is different from most others and what your treatment options look like.

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

In the U.S., the average lifetime risk of multiple myeloma is less than 1%. In 2025, the American Cancer Society estimates that 36,110 new cases of multiple myeloma will be diagnosed, affecting ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

We diagnose multiple myeloma by doing blood, urine, bone marrow, and imaging tests. The disease can be classified as being “smoldering myeloma,” which is typically closely monitored, and “active ...

Your multiple myeloma prognosis—meaning the estimated course of the disease—depends on factors like your age, overall health, ...

Smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS) are conditions that can happen before multiple myeloma, but these conditions don’t usually need treatment. At Fred ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.